{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-070706","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.004633+00:00","generated_at":"2026-06-04T13:27:27.654075+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Crinetics paltusotine meets all endpoints in Phase 3 acromegaly study; NDA planned 2H 2024","bullets":["Primary endpoint: 56% of paltusotine patients achieved IGF-1 ≤1.0 xULN vs 5% placebo (p<0.0001).","All secondary endpoints met: IGF-1 change, GH <1.0 ng/mL, and Acromegaly Symptoms Diary score.","No serious adverse events reported; common TEAEs included diarrhea, headache, arthralgia, abdominal pain.","Crinetics to submit NDA to FDA in 2H 2024; potential launch in 2025.","PATHFNDR-2 enrolled 111 untreated acromegaly patients in a 24-week placebo-controlled trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-070706","json":"https://secwatch.observer/filing/0001193125-24-070706.json","markdown":"https://secwatch.observer/filing/0001193125-24-070706.md","text":"https://secwatch.observer/filing/0001193125-24-070706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524070706/0001193125-24-070706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524070706/d814079d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:27:27.654075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}